Every 10-Q that Veru Inc. (VERU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VERU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERU filings page.
Veru Inc. reported continued losses for the quarter and nine months ended June 30, 2026 as it transitions to a pure drug development business focused on enobosarm for obesity in older adults on GLP‑1 therapies and sabizabulin for atherosclerotic cardiovascular disease. The company had $23.9 million in cash, cash equivalents and restricted cash and $37.0 million in total assets, with $8.7 million in total liabilities and $28.4 million of stockholders’ equity.
For the nine months, Veru generated no revenue from continuing operations, recorded an operating loss of $20.4 million and a net loss of $15.1 million, improved from a $24.2 million loss a year earlier, aided by a $4.4 million gain from equity securities. Net cash used in operating activities was $20.6 million. Management states that existing cash is insufficient to fund the next 12 months under its current plan and concludes there is substantial doubt about the company’s ability to continue as a going concern absent additional financing.
Liquidity was bolstered by $23.4 million of net proceeds from an October 2025 underwritten offering and $5.3 million of net cash from investing activities, including monetization of its ENTADFI-related ONCO stake. Veru previously sold its FC2 business, which is now fully in discontinued operations, and in July 2026 put a $21.8 million at‑the‑market equity program in place.
Veru Inc. reported a smaller net loss while remaining a pre‑revenue, late‑stage biotech focused on enobosarm and sabizabulin. For the six months ended March 31, 2026, net loss was $8.1 million versus $16.8 million a year earlier, helped by a $3.8 million gain on equity securities and lower operating expenses.
The company had $27.6 million in cash, cash equivalents, and restricted cash and used $15.1 million in operating cash over six months. Management states there is substantial doubt about Veru’s ability to continue as a going concern over the next 12 months without additional capital.
Veru sold its FC2 condom business and ENTADFI rights, reshaping itself around obesity and cardiovascular drug candidates. It raised about $23.4 million in an October 2025 equity offering that included common stock, pre‑funded warrants, and 16.8 million tradable warrants, but now depends on future financings to fund development.
Veru Inc. reported a net loss of $5.3 million for the quarter ended December 31, 2025, improving from a $8.9 million loss a year earlier as operating expenses fell to $5.4 million from $10.9 million, mainly from lower research and development spending.
The company generated no revenue from continuing operations after selling its FC2 condom business in 2024 and is now focused on late-stage drug candidates enobosarm for obesity and sabizabulin for cardiovascular inflammation. Cash, cash equivalents, and restricted cash rose to $33.0 million from $15.8 million, largely driven by a public offering that raised about $23.4 million from common stock, pre-funded warrants and 16.8 million tradable warrants.
Management disclosed that current cash is expected to be insufficient to fund operations for 12 months after the financial statement issuance date without new capital, leading to a “substantial doubt” going concern warning. The business now operates as a single drug development segment, with liquidity and future progress dependent on successful financing and advancement of clinical programs.
Veru Inc. reported a quarterly net loss of $7.33 million for the three months ended June 30, 2025, narrower than the prior-year quarter loss of $10.97 million, driven by lower operating expenses with research and development falling to $3.02 million and selling, general and administrative to $5.01 million. The company recorded no net revenues in the quarter and reported net loss per share of $0.50 versus $0.75 a year earlier.
Cash and restricted cash totaled $15.01 million at June 30, 2025, down from $24.92 million at September 30, 2024. Net cash used in operating activities for the nine months was $24.55 million. The company completed the sale of its FC2 business, generating expected net proceeds of approximately $16.3 million and recognizing a $4.3 million loss on the sale, and recognized an $8.6 million gain on extinguishment of debt related to the residual royalty agreement. Management discloses substantial doubt about the Company’s ability to continue as a going concern for at least twelve months.